10.1021/op700222r
The research focuses on the development of an efficient synthetic route for the manufacture of N-[5-(3-Imidazol-1-yl-4methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]acetamide, a potent candidate for respiratory treatments, specifically aimed at asthma. The new synthesis route addresses toxicity and safety issues from the original process by utilizing a key Darzens condensation and α,β-epoxide rearrangement, enhancing the practicality, robustness, and streamlining of the manufacturing process. The experiments involved a series of chemical reactions, including SNAr reactions, Henry condensation, reduction of nitro compounds, and the formation of heterocyclic moieties. Reactants such as 3,4-difluorobenzaldehyde, sodium methylsulfinate, nitroethane, and various other reagents were used. The analyses included monitoring reaction temperatures, yields, purities, and the use of techniques like NMR spectroscopy and high-resolution mass spectrometry (HRMS) to characterize the intermediates and final products. The study also explored alternative solvent systems and conditions to improve the overall yield and safety of the process.